The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans.

ABSTRACT: Conjugation or fusion to AlbudAbs™ (albumin-binding domain antibodies) is a novel approach to extend the half-life and alter the tissue distribution of biological and small molecule therapeutics. To understand extravasation kinetics and extravascular organ concentrations of AlbudAbs in humans, we studied tissue distribution and elimination of a non-conjugated ⁸⁹Zr-labeled AlbudAb in healthy volunteers using positron emission tomography/computed tomography (PET/CT).

Methods

A non-conjugated AlbudAb (GSK3128349) was radiolabeled with ⁸⁹Zr and a single 1 mg (~ 15 MBq) dose intravenously administered to eight healthy males. ⁸⁹Zr-AlbudAb tissue distribution was followed for up to 7 days with four whole-body PET/CT scans. ⁸⁹Zr-AlbudAb tissue con

SUBMITTER: Thorneloe KS 

PROVIDER: S-EPMC6529487 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature